Search form

Search form

The European Medicines Agency has recommended that doctors resume prescribing the full dose of Genzyme's Fabry disease drug Fabrazyme after the agency found a steady increase in adverse events among patients receiving a lower dose. Dosing of the treatment was reduced last year because of a supply shortage prompted by issues at Genzyme's manufacturing facility.

Farm machinery manufacturers and agribusiness companies are collaborating on a project in Iowa to develop collection, storage and transportation systems for corn stover for cellulosic biofuels. "The insights gained from this research will advance our understanding of the volume potential and economics of corn stover as a biomass feedstock for advanced biofuels," according to Archer Daniels Midland, one of the companies involved.

The FDA has denied a proposal by ViroPharma to expand manufacturing of Cinryze, a treatment for hereditary angioedema, to industrial scale. In a complete-response letter, the FDA requested additional information on the technical process and asked for ViroPharma's response to the agency's "quality observations" during a recent inspection.

The European Medicines Agency has recommended that doctors resume prescribing the full dose of Genzyme's Fabry disease drug Fabrazyme after the agency found a steady increase in adverse events among patients receiving a lower dose. Dosing of the treatment was reduced last year because of a supply shortage prompted by issues at Genzyme's manufacturing facility.

Eli Lilly and Co. might consider acquiring Amylin Pharmaceuticals or broaden its painkiller business by buying companies such as Cephalon and Endo Pharmaceuticals after the drug giant failed to get FDA approval for Bydureon, a diabetes drug candidate, and halted clinical trials of another diabetes treatment, analysts said. Meanwhile, Lilly CEO John Lechleiter said the company is more interested in making small acquisitions than "large-scale combinations."